EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-2024-review

More Like This

PR Newswire associated0

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

PR Newswire associated0

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

PR Newswire associated0

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

PR Newswire associated0

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.